Measuring the Glycemic Index and Tracking Metabolites of New and Emerging Lentil Varieties

NCT02909803 | Completed

• 1 other identifier: Lentil metabolites
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

It is not known whether different lentil varieties have the same efficacy in lowering blood glucose. Similarly, the carbohydrate component of lentils responsible for lowering blood glucose is not known, nor is the bioavailability of lentil metabolites and polyphenol bioactive.

Conditions

Hyperglycemia; Dietary Modification

Keywords

glucose; glycemic index; lentil; polyphenols; metabolites; bioavailability

Outcome Measures

Primary Outcomes (1)

• Glycemic Response

  Incremental blood glucose response after eating the test or control foods will be measured over a period of 120 minutes using finger prick blood samples collected at time 0, 15, 30, 45, 60, 90, 120 minutes.

  120 minutes after consuming each test or control food

Secondary Outcomes (1)

• Lentil metabolites in blood and urine

  Urine and additional 200uL blood samples will be collected before eating test meal and at 120 minutes after.

Study Arms (2)

Lentil Variety

EXPERIMENTAL

Each participant will consume a serving of one of eight lentil varieties (Greenland; Improve; Impower; Imigreen; Asterix; Redberry; Redcliff; Redbow) containing 25g available carbohydrate at separate study visits

Other: Lentil Variety

White Bread

ACTIVE COMPARATOR

Each participant will consume a serving of white bread containing 25g available carbohydrate on two separate visits

Other: White Bread

Interventions

Lentil Variety OTHER

Participants will consume 8 varieties of lentils that are cooked by boiling

Lentil Variety

White Bread OTHER

Participants will consume white bread on at least two different test days

White Bread

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or non-pregnant females, 18-75 years of age, inclusive
• Body mass index (BMI) \< 40 kg/m²
• Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial and to refrain from smoking for 12hr prior to each visit.
• Normal fasting serum glucose (\<7.0mmol/L capillary corresponding to whole blood glucose \<6.3mmol/L).
• Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator.

You may not qualify if:

• Known history of AIDS, hepatitis, diabetes or a heart condition
• Subjects using medications or with any condition which might, in the opinion of Dr. Wolever, the Medical Director of GI Labs, either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
• Major trauma or surgical event within 3 months of screening.
• Unwillingness or inability to comply with the experimental procedures and to follow GI Labs safety guidelines.
• Known intolerance, sensitivity or allergy to any ingredients in the study products.

Sponsors & Collaborators

• Guelph Food Research Centre: lead
• Glycemic Index Laboratories, Inc: collaborator
• University of Manitoba: collaborator

Study Sites (1)

Glycemic Index Laboratories, Inc

Toronto, Ontario, M5C 2N8, Canada

Location

Related Publications (5)

• Health Canada. Bureau of Nutritional Sciences, food directorate, health products and food branch. June 2013. Draft guidance document on food health claims related to the reduction in post-prandial glycaemic response

  BACKGROUND

• Wolever TM, Jenkins DJ. The use of the glycemic index in predicting the blood glucose response to mixed meals. Am J Clin Nutr. 1986 Jan;43(1):167-72. doi: 10.1093/ajcn/43.1.167.

  PMID: 3942088 BACKGROUND

• Wolever TMS (2006). The Glycaemic Index: A Physiological Classification of Dietary Carbohydrate. CABI Publishing, Wallingford, UK.

  BACKGROUND

• Ramdath D, Renwick S, Duncan AM. The Role of Pulses in the Dietary Management of Diabetes. Can J Diabetes. 2016 Aug;40(4):355-63. doi: 10.1016/j.jcjd.2016.05.015.

  PMID: 27497151 BACKGROUND

• Wang, L., Zahradka, P., Taylor, C. and Aliani, M., Metabolomics Analysis of Serum and Urine After Bean Consumption by Patients with Peripheral Arterial Disease. The FASEB Journal, 30(1 Supplement): 682-10, 2016.

  BACKGROUND

MeSH Terms

Conditions

Hyperglycemia

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Dan Ramdath, PhD

  Guelph Research and Development Centre

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Research Scientist

Study Record Dates

• First Submitted: September 15, 2016
• First Posted: September 21, 2016
• Study Start: January 1, 2013
• Primary Completion: March 1, 2013
• Study Completion: July 1, 2016
• Last Updated: September 21, 2016

Record last verified: 2016-09

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)